Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 30

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

Chau, Cindy H., Price, Douglas K., Till, Cathee, Goodman, Phyllis J., Chen, Xiaohong, Leach, Robin J., Johnson-Pais, Teresa L., Hsing, Ann W., Hoque, Ashraful, Tangen, Catherine M., Chu, Lisa, Parnes, Howard L., Schenk, Jeannette M., Reichardt, Juergen K. V., Thompson, Ian M., Figg, William D.·2015·PLOS ONE
DOI 10.1371/journal.pone.0126672
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0126672

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 27

  1. N Bruchovsky, 1968, The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro, J Biol Chem, 243, 2012, 10.1016/S0021-9258(18)93542-8 · DOI
  2. J Imperato-McGinley, 1974, Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism, Science, 186, 1213, 10.1126/science.186.4170.1213 · DOI · Paper page
  3. S Andersson, 1990, Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases, Proc Natl Acad Sci U S A, 87, 3640, 10.1073/pnas.87.10.3640 · DOI · Paper page
  4. K Tamura, 2007, Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles, Cancer Res, 67, 5117, 10.1158/0008-5472.CAN-06-4040 · DOI
  5. UB Chaudhary, 2010, Finasteride, Expert Opin Drug Metab Toxicol, 6, 873, 10.1517/17425255.2010.495944 · DOI
  6. GJ Gormley, 1992, The Effect of Finasteride in Men with Benign Prostatic Hyperplasia, N Engl J Med, 327, 1185, 10.1056/NEJM199210223271701 · DOI
  7. E Stoner, 1992, The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group, J Urol, 147, 1298, 10.1016/S0022-5347(17)37547-X · DOI
  8. HG Bull, 1996, Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP—Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor, J Am Chem Soc, 118, 2359, 10.1021/ja953069t · DOI
  9. K Yamana, 2010, Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride, Horm Mol Biol Clin Invest, 2, 293
  10. NM Makridakis, 2000, Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II, Pharmacogenetics, 10, 407, 10.1097/00008571-200007000-00004 · DOI
  11. N Makridakis, 2004, Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue, Oncogene, 23, 7399, 10.1038/sj.onc.1207922 · DOI
  12. SW Huskey, 1995, Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride, Drug Metab Dispos, 23, 1126, 10.1016/S0090-9556(25)06757-1 · DOI
  13. P Kuehl, 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, 27, 383, 10.1038/86882 · DOI
  14. IM Thompson, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, 215, 10.1056/NEJMoa030660 · DOI
  15. P Feigl, 1995, Design of the Prostate Cancer Prevention Trial (PCPT), Control Clin Trials, 16, 150, 10.1016/0197-2456(94)00XXX-M · DOI
  16. X Chen, 2008, Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis, J Chromatogr Sci, 46, 356, 10.1093/chromsci/46.4.356 · DOI
  17. JC Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457 · DOI · Paper page
  18. SB Gabriel, 2002, The structure of haplotype blocks in the human genome, Science, 296, 2225, 10.1126/science.1069424 · DOI · Paper page
  19. Z Gong, 2009, Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial, Cancer, 115, 3661, 10.1002/cncr.24423 · DOI
  20. BX He, 2011, A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population, Basic Clin Pharmacol Toxicol, 108, 208, 10.1111/j.1742-7843.2010.00657.x · DOI
  21. Y Gao, 2008, CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin, Eur J Clin Pharmacol, 64, 877, 10.1007/s00228-008-0502-x · DOI
  22. M Miura, 2011, Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients, Pharmacogenomics, 12, 977, 10.2217/pgs.11.33 · DOI
  23. M Schirmer, 2007, Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes, Pharmacogenomics, 8, 443, 10.2217/14622416.8.5.443 · DOI
  24. RH van Schaik, 2001, The CYP3A4*3 allele: is it really rare?, Clin Chem, 47, 1104, 10.1093/clinchem/47.6.1104 · DOI
  25. DH Kim, 2009, Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia, Clin Cancer Res, 15, 4750, 10.1158/1078-0432.CCR-09-0145 · DOI
  26. J Garcia-Donas, 2011, Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study, Lancet Oncol, 12, 1143, 10.1016/S1470-2045(11)70266-2 · DOI
  27. M Onizuka, 2011, Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients, Bone Marrow Transplant, 46, 1113, 10.1038/bmt.2010.273 · DOI

Cited by

Metadata

Authors
Chau, C. H., Price, D. K., Till, C., Goodman, P. J., Chen, X., Leach, R. J., Johnson-Pais, T. L., Hsing, A. W., Hoque, A., Tangen, C. M., Chu, L., Parnes, H. L., Schenk, J. M., Reichardt, J. K. V., Thompson, I. M., & Figg, W. D.
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2015-05-08
Volume
10
Issue
5
Pages
e0126672
ISSN
1932-6203
DOI
10.1371/journal.pone.0126672
Cited by
30
References
1
Language
en
Licence
creativecommons.org/publicdomain/zero/1.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.